Targeting the immune-privileged myofibroblast in oral submucous fibrosis by CAR T-cell therapy

Radhakrishnan, Raghu (2022) Targeting the immune-privileged myofibroblast in oral submucous fibrosis by CAR T-cell therapy. Medical Hypotheses, 165. pp. 1-4. ISSN 0306-9877

[img] PDF
16033.pdf - Published Version
Restricted to Registered users only

Download (3MB) | Request a copy


Despite several advancements in understanding the pathogenesis of oral submucous fibrosis (OSMF), there is no definitive therapy for the complete remission of the disease process. This is attributed to the fact that any chronic fibrotic disease targeting myofibroblasts, the primary cells responsible for fibrosis is challenging. The betel quidassociated chemicals, predominantly, arecoline and arecaidine, advance the activation of resident fibroblasts to myofibroblasts in OSMF, resulting in uncontrolled and excessive production of collagen. The myofibroblasts,which are associated with the malignant transformation express fibroblast-activating protein (FAP) on their surface that could be selectively targeted for the treatment of OSMF. In the present paper, we propose that the adoptive transfer of T cells that express a chimeric antigen receptor against fibroblast activation protein (FAP CAR T cell therapy) results in a significant reduction in fibrosis and restoration of function in OSMF. The detailed procedural aspects of this therapy along with experimental designs are also discussed. Since myofibroblasts are involved in the malignant transformation of OSMF, the selective elimination of these cells will reduce the cancer development and ultimately the cancer burden

Item Type: Article
Uncontrolled Keywords: Oral submucous fibrosis; CAR T-cell; Immunotherapy; Myofibroblasts; Fibroblast stimulating protein
Subjects: Dentistry > MCODS Manipal > Oral Pathology and Microbiology
Depositing User: KMC Library
Date Deposited: 09 Sep 2022 08:37
Last Modified: 09 Sep 2022 08:37

Actions (login required)

View Item View Item